Background:
Predictive biomarkers for optimal treatment selection in RCC are lacking. Gene expression profiling (GEP) studies have identified angiogenic and immune sig. with potential predictive value in patients (pts) with advanced ccRCC. We aimed to update the findings of a large multi-institutional database (Barata, ASCO-GU 21), with a focus on tumors with sarcomatoid/rhabdoid features.